The legacy of general health and science information has long emphasized broad wellness principles, disease prevention, and accessible medical guidance for diverse populations. This foundational context includes public health messaging about routine screenings, lifestyle factors, and the importance of evidence-based care. Within this framework, discussions of cancer risk have traditionally focused on modifiable behaviors, genetic predisposition, and environmental exposures in everyday settings. However, as clinical knowledge advances, the scope of health information must expand to address specific therapeutic agents and their potential unintended consequences. In the domain of mass production, particularly in pharmaceutical manufacturing and healthcare delivery, workers may encounter biological or chemical agents that warrant focused scrutiny. One such agent is Avelumab, a monoclonal antibody approved for certain malignancies, including Merkel cell carcinoma. While its therapeutic benefits are established, occupational exposure scenarios—such as accidental dermal contact, inhalation, or needlestick injuries during production or administration—raise questions about causation pathways. This transition pivots from general health literacy to a targeted occupational exposure concern: evaluating whether Avelumab exposure in workplace settings could be associated with Merkel cell carcinoma risk. The following review examines clinical evidence to clarify this potential link, moving beyond population-level health advice to address specific industrial hygiene and safety considerations.
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 trial, a two-part, single-arm phase II study in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). As an immune checkpoint inhibitor, avelumab blocks PD-L1, thereby enhancing T-cell-mediated antitumor immune responses. However, this mechanism can lead to overactivation of the immune system, resulting in immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC treated with avelumab; the hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that avelumab can trigger irAEs beyond typical dermatologic or endocrine toxicities.
Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381/). It is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Diagnosis typically involves histopathological examination and immunohistochemical staining to confirm neuroendocrine features.
The primary link between avelumab and MCC is therapeutic: avelumab is used to treat MCC by inhibiting PD-L1, thereby restoring immune surveillance against tumor cells. However, a subset of patients becomes refractory to avelumab. In avelumab-refractory MCC, response rates to PD-1/PD-L1 inhibition are lower; for example, response rates to PD-1/PD-L1 inhibitors in metastatic MCC can reach up to 62%, but approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, alternative treatments such as combined ipilimumab plus nivolumab have been investigated. In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab showed activity in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Similarly, a retrospective study at three German sites found that three out of five avelumab-refractory patients responded to combined ipilimumab/nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). These findings indicate that resistance to avelumab may involve mechanisms that can be overcome by dual checkpoint blockade.
Adequacy of warnings: The prescribing information for avelumab includes warnings about immune-mediated adverse reactions, but specific warnings regarding MCC progression or refractoriness are not highlighted in the available evidence. The risk of progression on avelumab is substantial, with approximately 50% of advanced MCC patients not responding to immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/35877101/). For affected patients, causation considerations involve the timeline between avelumab exposure and documented harm. In the JAVELIN Merkel 200 trial, responses were assessed at standard intervals, but the evidence does not provide a precise timeline for progression. In the case of hypercalcaemia due to sarcoidosis, the adverse event occurred during treatment, and resolution followed corticosteroid administration (https://pubmed.ncbi.nlm.nih.gov/31543781/). For avelumab-refractory patients, the timeline from initiation of avelumab to documented progression is variable and depends on individual tumor biology and prior treatments.
Patients who experience progression on avelumab may face limited treatment options, as efficient and safe therapies for avelumab-refractory MCC are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). The evidence suggests that combined ipilimumab plus nivolumab can be effective in some avelumab-refractory cases, but this is based on small retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). Clinicians should monitor patients for signs of progression and irAEs, and consider alternative checkpoint inhibitor combinations when appropriate.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting PD-L1 (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) based on the JAVELIN Merkel 200 trial, which showed objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).
No, Avelumab is used to treat Merkel cell carcinoma, not cause it. However, a subset of patients may become refractory to Avelumab, and approximately 50% of advanced MCC patients do not respond to immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/35877101/). The primary concern is progression on therapy, not causation of the disease.
Occupational exposure to Avelumab, such as accidental dermal contact, inhalation, or needlestick injuries during production or administration, may pose risks. However, the clinical evidence primarily focuses on therapeutic use. The prescribing information includes warnings about immune-mediated adverse reactions, but specific occupational exposure risks are not well-documented.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.